Molecular pathogenesis of pancreatic cancer.

Our understanding of the biology of pancreatic carcinoma has greatly benefited from studies of the genetic alterations in this tumor type. The p16-CDK4-cyclinD-Rb pathway, the p53 tumor suppressor pathway, and the DPC4/Smad4 pathway are genetically inactivated in the majority of sporadic pancreatic carcinomas, whereas oncogenic K-ras signaling is almost ubiquitously activated. These genetic data have provided the basis to shape a first genetic progression model of this tumor type. Furthermore, a number of well defined genetic syndromes which are associated with an inherited risk for pancreatic carcinoma have been identified recently.

[1]  M. Skolnick,et al.  Human mitogen-activated protein kinase kinase 4 as a candidate tumor suppressor. , 1997, Cancer research.

[2]  L. Aaltonen,et al.  Mutations in the SMAD4/DPC4 gene in juvenile polyposis. , 1998, Science.

[3]  W. Schmiegel,et al.  DPC4/SMAD4 mediated tumor suppression of colon carcinoma cells is associated with reduced urokinase expression , 1999, Oncogene.

[4]  P. Meltzer,et al.  Specific chromosomal aberrations and amplification of the AIB1 nuclear receptor coactivator gene in pancreatic carcinomas. , 1999, The American journal of pathology.

[5]  D. B. Berman,et al.  Frequency of recurrent BRCA1 and BRCA2 mutations in Ashkenazi Jewish breast cancer families , 1996, Nature Medicine.

[6]  G. Stein,et al.  Failure to phosphorylate the retinoblastoma gene product in senescent human fibroblasts. , 1990, Science.

[7]  S. Saga,et al.  Relation of pancreatic duct hyperplasia to carcinoma , 1979, Cancer.

[8]  R H Hruban,et al.  Pancreatic Intraepithelial Neoplasia: A New Nomenclature and Classification System for Pancreatic Duct Lesions , 2001, The American journal of surgical pathology.

[9]  J. Massagué.  TGFβ Signaling: Receptors, Transducers, and Mad Proteins , 1996, Cell.

[10]  A M Goldstein,et al.  Increased risk of pancreatic cancer in melanoma-prone kindreds with p16INK4 mutations. , 1995, The New England journal of medicine.

[11]  M. Skolnick,et al.  A cell cycle regulator potentially involved in genesis of many tumor types. , 1994, Science.

[12]  S. Goodman,et al.  Tumor-suppressive pathways in pancreatic carcinoma. , 1997, Cancer research.

[13]  M. Gorry,et al.  Hereditary pancreatitis is caused by a mutation in the cationic trypsinogen gene , 1996, Nature Genetics.

[14]  J. Cameron,et al.  Detection of K-ras mutations in mucinous pancreatic duct hyperplasia from a patient with a family history of pancreatic carcinoma. , 1994, The American journal of pathology.

[15]  R. Hruban,et al.  High‐resolution deletion mapping of chromosome arm 1p in pancreatic cancer identifies a major consensus region at 1p35 , 1999, Genes, chromosomes & cancer.

[16]  W. Schmiegel,et al.  Frequent codeletion of p16/MTS1 and p15/MTS2 and genetic alterations in p16/MTS1 in pancreatic tumors. , 1996, Gastroenterology.

[17]  G. Klöppel,et al.  The K‐ras mutation pattern in pancreatic ductal adenocarcinoma usually is identical to that in associated normal, hyperplastic, and metaplastic ductal epithelium , 1999, Cancer.

[18]  H. Watanabe,et al.  Genetic progression and divergence in pancreatic carcinoma. , 2000, The American journal of pathology.

[19]  H. Lynch,et al.  Pancreatic carcinoma and hereditary nonpolyposis colorectal cancer: a family study. , 1985, British Journal of Cancer.

[20]  C. Moskaluk,et al.  p16 and K-ras gene mutations in the intraductal precursors of human pancreatic adenocarcinoma. , 1997, Cancer research.

[21]  Jiahuai Han,et al.  Independent human MAP-kinase signal transduction pathways defined by MEK and MKK isoforms , 1995, Science.

[22]  S. Kern,et al.  INK4 genes in pancreatic carcinoma. , 1996, Oncology Report.

[23]  B. Sipos,et al.  Duct changes and K-ras mutations in the disease-free pancreas: analysis of type, age relation and spatial distribution , 1999, Virchows Archiv.

[24]  G. Riggins,et al.  Analysis of PTEN/MMAC1 alterations in aerodigestive tract tumors. , 1998, Cancer research.

[25]  G. Elia,et al.  Abnormalities of the RB1 and DCC tumor suppressor genes: Uncommon in human pancreatic adenocarcinoma , 1995, Molecular Carcinogenesis.

[26]  R. Hruban,et al.  Genomic FHIT analysis in RER+ and RER− adenocarcinomas of the pancreas , 2000, Genes, chromosomes & cancer.

[27]  W. Schmiegel,et al.  Allelic loss is often the first hit in the biallelic inactivation of the p53 and DPC4 genes during pancreatic carcinogenesis. , 2001, The American journal of pathology.

[28]  R. Hruban,et al.  p53 mutations in pancreatic carcinoma and evidence of common involvement of homocopolymer tracts in DNA microdeletions. , 1994, Cancer research.

[29]  H. Yamamoto,et al.  Adenocarcinomas with Widespread Microsatellite Instability Genetic and Clinical Features of Human Pancreatic Ductal Updated , 2001 .

[30]  C. Sherr.  Cancer Cell Cycles , 1996, Science.

[31]  N. Pellegata,et al.  K-ras and p53 gene mutations in pancreatic cancer: ductal and nonductal tumors progress through different genetic lesions. , 1994, Cancer research.

[32]  J. Rüschoff,et al.  Molecular analysis of microdissected tumors and preneoplastic intraductal lesions in pancreatic carcinoma. , 2000, The American journal of pathology.

[33]  R H Hruban,et al.  Familial pancreatic cancer: a review. , 1996, Seminars in oncology.

[34]  S. Kern,et al.  Homozygous deletions inactivate DCC, but not MADH4/DPC4/SMAD4, in a subset of pancreatic and biliary cancers , 2000, Genes, chromosomes & cancer.

[35]  V. Rotter,et al.  Mutant p53 proteins bind DNA abnormally in vitro. , 1991, Oncogene.

[36]  M. Masu,et al.  Deleted in Colorectal Cancer (DCC) Encodes a Netrin Receptor , 1996, Cell.

[37]  D. Shibata,et al.  Most human carcinomas of the exocrine pancreas contain mutant c-K-ras genes , 1988, Cell.

[38]  R. Hruban,et al.  Loss of expression of Dpc4 in pancreatic intraepithelial neoplasia: evidence that DPC4 inactivation occurs late in neoplastic progression. , 2000, Cancer research.

[39]  S. Stryker,et al.  Expression of p53 protein in precursor lesions and adenocarcinoma of human pancreas. , 1994, The American journal of pathology.

[40]  P. Peltomäki,et al.  Deficient DNA mismatch repair: a common etiologic factor for colon cancer. , 2001, Human molecular genetics.

[41]  M. Choti,et al.  Genetic, immunohistochemical, and clinical features of medullary carcinoma of the pancreas: A newly described and characterized entity. , 2000, The American journal of pathology.

[42]  C Caldas,et al.  Allelotype of pancreatic adenocarcinoma. , 1994, Cancer research.

[43]  R. Hruban,et al.  Inactivation of the p16 (INK4A) tumor-suppressor gene in pancreatic duct lesions: loss of intranuclear expression. , 1998, Cancer research.

[44]  Scott E. Kern,et al.  Evaluation of candidate tumour suppressor genes on chromosome 18 in colorectal cancers , 1996, Nature Genetics.

[45]  R. Hruban,et al.  Germline and somatic mutations of the STK11/LKB1 Peutz-Jeghers gene in pancreatic and biliary cancers. , 1999, The American journal of pathology.

[46]  K. Kinzler,et al.  Serial Analysis of Gene Expression , 1995, Science.

[47]  O. Volpert,et al.  Smad4/DPC4-mediated tumor suppression through suppression of angiogenesis. , 2000, Proceedings of the National Academy of Sciences of the United States of America.

[48]  S. Goodman,et al.  K-ras oncogene activation in adenocarcinoma of the human pancreas. A study of 82 carcinomas using a combination of mutant-enriched polymerase chain reaction analysis and allele-specific oligonucleotide hybridization. , 1993, The American journal of pathology.

[49]  T. Hunter,et al.  Cyclins and cancer II: Cyclin D and CDK inhibitors come of age , 1994, Cell.

[50]  S. Goodman,et al.  Overexpression of p53 protein in adenocarcinoma of the pancreas. , 1994, American journal of clinical pathology.

[51]  E. Rosato,et al.  Fragile histidine triad expression delays tumor development and induces apoptosis in human pancreatic cancer. , 2001, Cancer research.

[52]  W. Schmiegel,et al.  Mutations of the DPC4/Smad4 gene in biliary tract carcinoma. , 1998, Cancer research.

[53]  P. Lichter,et al.  Mapping of chromosomal imbalances in pancreatic carcinoma by comparative genomic hybridization. , 1996, Cancer research.

[54]  V. Rotter,et al.  Oncogenic mutations of the p53 tumor suppressor: the demons of the guardian of the genome. , 2000, Cancer research.

[55]  M. Mann,et al.  Proteomics to study genes and genomes , 2000, Nature.

[56]  J. Sekelsky,et al.  Genetic characterization and cloning of mothers against dpp, a gene required for decapentaplegic function in Drosophila melanogaster. , 1995, Genetics.

[57]  A. Gazdar,et al.  K-ras mutations and allelic loss at 5q and 18q in the development of human pancreatic cancers , 1997, International journal of pancreatology : official journal of the International Association of Pancreatology.

[58]  Longnecker Ds.  THE QUEST FOR PRENEOPLASTIC LESIONS IN THE PANCREAS , 1994 .

[59]  C. Moskaluk,et al.  Novel germline p16(INK4) allele (Asp145Cys) in a family with multiple pancreatic carcinomas. Mutations in brief no. 148. Online. , 1998, Human mutation.

[60]  H. Friess,et al.  Characterization of a high copy number amplification at 6q24 in pancreatic cancer identifies c-myb as a candidate oncogene. , 1997, Cancer research.

[61]  C. Moskaluk,et al.  Novel germline p16INK4 allele (Asp145Cys) in a family with multiple pancreatic carcinomas , 1998 .

[62]  D L Rimm,et al.  Beta- and gamma-catenin mutations, but not E-cadherin inactivation, underlie T-cell factor/lymphoid enhancer factor transcriptional deregulation in gastric and pancreatic cancer. , 1999, Cell growth & differentiation : the molecular biology journal of the American Association for Cancer Research.

[63]  D. Brat,et al.  The structural basis of molecular genetic deletions. An integration of classical cytogenetic and molecular analyses in pancreatic adenocarcinoma. , 1997, The American journal of pathology.

[64]  J. Cheng,et al.  Amplification of AKT2 in human pancreatic cells and inhibition of AKT2 expression and tumorigenicity by antisense RNA. , 1996, Proceedings of the National Academy of Sciences of the United States of America.

[65]  K. Kinzler,et al.  Lessons from Hereditary Colorectal Cancer , 1996, Cell.

[66]  Yigong Shi,et al.  Crystal Structure of a Smad MH1 Domain Bound to DNA Insights on DNA Binding in TGF-β Signaling , 1998, Cell.

[67]  J. Cameron,et al.  Increased risk of incident pancreatic cancer among first-degree relatives of patients with familial pancreatic cancer. , 2001, Clinical cancer research : an official journal of the American Association for Cancer Research.

[68]  R. Hruban,et al.  Pancreatic adenocarcinomas with DNA replication errors (RER+) are associated with wild-type K-ras and characteristic histopathology. Poor differentiation, a syncytial growth pattern, and pushing borders suggest RER+. , 1998, The American journal of pathology.

[69]  A. Cubilla,et al.  Morphological lesions associated with human primary invasive nonendocrine pancreas cancer. , 1976, Cancer research.

[70]  T. Smyrk,et al.  Familial pancreatic cancer: clinicopathologic study of 18 nuclear families. , 1990, The American journal of gastroenterology.

[71]  R. Hruban,et al.  Detection of K-ras mutations in the stool of patients with pancreatic adenocarcinoma and pancreatic ductal hyperplasia. , 1994, Cancer research.

[72]  Scott E. Kern,et al.  DPC4, A Candidate Tumor Suppressor Gene at Human Chromosome 18q21.1 , 1996, Science.

[73]  G. Lauer,et al.  p53 and K-RAS alterations in pancreatic epithelial cell lesions. , 1993, Oncogene.

[74]  C. Moskaluk,et al.  Homozygous deletion map at 18q21.1 in pancreatic cancer. , 1996, Cancer research.

[75]  S. Bohlander,et al.  Consistent chromosome abnormalities in adenocarcinoma of the pancreas. , 1995, Cancer research.

[76]  Bert Vogelstein,et al.  Somatic mutations of the mitochondrial genome in human colorectal tumours , 1998, Nature Genetics.

[77]  Y. Takagi,et al.  Somatic alterations of the DPC4 gene in human colorectal cancers in vivo. , 1996, Gastroenterology.

[78]  Takeo Iwama,et al.  Higher frequency of Smad4 gene mutation in human colorectal cancer with distant metastasis , 1999, Oncogene.

[79]  Kohei Miyazono,et al.  TGF-β signalling from cell membrane to nucleus through SMAD proteins , 1997, Nature.

[80]  R. Hruban,et al.  Allelotype of pancreatic adenocarcinoma using xenograft enrichment. , 1995, Cancer research.

[81]  G Parmigiani,et al.  Detection of mitochondrial DNA mutations in pancreatic cancer offers a "mass"-ive advantage over detection of nuclear DNA mutations. , 2001, Cancer research.

[82]  Y. Shiratori,et al.  Analysis of K-ras gene mutation in hyperplastic duct cells of the pancreas without pancreatic disease. , 1996, Gastroenterology.

[83]  C. Moskaluk,et al.  Germline BRCA2 gene mutations in patients with apparently sporadic pancreatic carcinomas. , 1996, Cancer research.

[84]  E. Montgomery,et al.  すい臓癌におけるACVR1B(ALK4、1B型アクチビン受容体)遺伝子の突然変異 , 2001 .

[85]  R. Hruban,et al.  ACVR1B (ALK4, activin receptor type 1B) gene mutations in pancreatic carcinoma , 2001, Proceedings of the National Academy of Sciences of the United States of America.

[86]  G. Hannon,et al.  A new regulatory motif in cell-cycle control causing specific inhibition of cyclin D/CDK4 , 1993, Nature.

[87]  J. Jen,et al.  Facile detection of mitochondrial DNA mutations in tumors and bodily fluids. , 2000, Science.

[88]  R. Hruban,et al.  Alterations in pancreatic, biliary, and breast carcinomas support MKK4 as a genetically targeted tumor suppressor gene. , 1998, Cancer research.

[89]  Kathleen R. Cho,et al.  DPC4 gene in various tumor types. , 1996, Cancer research.

[90]  L. Aaltonen,et al.  Life‐time risk of different cancers in hereditary non‐polyposis colorectal cancer (hnpcc) syndrome , 1995, International journal of cancer.

[91]  S. Kern,et al.  Functional mapping of the MH1 DNA-binding domain of DPC4/SMAD4. , 2000, Nucleic acids research.

[92]  M. Wigler,et al.  PTEN, a Putative Protein Tyrosine Phosphatase Gene Mutated in Human Brain, Breast, and Prostate Cancer , 1997, Science.

[93]  S. Goodman,et al.  Very high risk of cancer in familial Peutz-Jeghers syndrome. , 2000, Gastroenterology.

[94]  R. Hruban,et al.  Genetic alterations of the transforming growth factor beta receptor genes in pancreatic and biliary adenocarcinomas. , 1998, Cancer research.

[95]  L. Tryggvadottir,et al.  Neoplastic diseases in families of breast cancer patients. , 1994, Journal of medical genetics.

[96]  R. Hruban,et al.  Frequent somatic mutations and homozygous deletions of the p16 (MTS1) gene in pancreatic adenocarcinoma , 1994, Nature Genetics.

[97]  J. Wrana,et al.  Smads as transcriptional co-modulators. , 2000, Current opinion in cell biology.

[98]  A. Levine.  p53, the Cellular Gatekeeper for Growth and Division , 1997, Cell.

[99]  C. Moskaluk,et al.  Abrogation of the Rb/p16 tumor-suppressive pathway in virtually all pancreatic carcinomas. , 1997, Cancer research.

[100]  A J Krush,et al.  Increased risk of cancer in the Peutz-Jeghers syndrome. , 1987, The New England journal of medicine.